Cost ‐effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer

CONCLUSIONSThis modeling analysis found that both single and dual checkpoint blockade could be significantly more effective for MSI ‐H/dMMR mCRC than chemotherapy, but they were not cost‐effective, largely because of drug costs. Decreases in drug pricing and/or the duration of maintenance nivolumab could make ipilimumab and nivolumab cost‐effective. Prospective clinical trials should be performed to explore the optimal dur ation of maintenance nivolumab.

Source: Cancer - October 21, 2018 Category: Cancer & Oncology Authors: Jacqueline N. Chu, Jin Choi, Sassan Ostvar, James A. Torchia, Kerry Lynn Reynolds, Angela Tramontano, Justin F. Gainor, Daniel C. Chung, Jeffrey W. Clark, Chin Hur Tags: Original Article Source Type: research